# Gannet

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gannet-b-v

- Industry: Materials
- Headquarters: Hengelo, Netherlands
- Website: www.gannetimplant.com
- Latest round: Series A (Dec 19, 2019)
- Investors on record: 2

## About

Gannet B.V. is a medical device company specializing in innovative solutions for femoral neck fracture fixation, enhancing surgical outcomes through advanced implant technology.Founded in 2014 and headquartered in Hengelo, Netherlands, Gannet B.V. focuses on developing medical devices, particularly for orthopedic applications. The company has successfully conducted two deals, with its most recent funding round occurring on December 19, 2019.Gannet specializes in medical devices, specifically focusing on the fixation of femoral neck fractures through its innovative Gannet fixation system. The core offering, the Gannet implant, is designed to provide optimal stability and promote primary bone healing, addressing high re-intervention rates associated with femoral neck fractures, which can be as high as 33%. The implant utilizes a unique tapping technique rather than traditional screwing, preserving fracture repositioning during surgery. This low-volume implant features expandable anchors and a flat, horizontal surface, enhancing mechanical stability while minimizing the risk of subsidence. Gannet's products are marketed to orthopedic surgeons and hospitals, particularly in Western Europe, aimed at improving surgical outcomes for patients with femoral neck fractures.Revenue generation for Gannet is structured around direct sales of its flagship Gannet fixation system to hospitals and surgical centers. Transactions are typically business-to-business, with hospitals procuring the implants for surgical procedures. Orders are placed based on inventory needs, often involving bulk purchasing agreements due to the necessity for consistent availability in surgical environments. Pricing plans reflect the advanced technology and clinical benefits of the Gannet system, potentially including volume discounts for larger orders. Given the specialized nature of its products, Gannet maintains relationships with healthcare providers, ensuring continuous supply and support of its innovative solutions for fracture management.In December 2019, Gannet B.V. raised an undisclosed amount of Series A funding from returning investor Health Innovations and new investor Oost NL, with unspecified additional investors participating in the round. This funding will be utilized to support the development of new products and expansion into new markets. Gannet is actively designing new implants to enhance their product line, with a focus on launching these innovations within the next two years. Additionally, the company plans to expand its presence in regions beyond Western Europe, targeting markets in North America and Asia by 2025.

## Funding rounds

- Series A, Dec 19, 2019 — Oost NL, Health Innovations
- Seed, Feb 3, 2014 — Health Innovations

## Investors

- Health Innovations (https://capitalatlas.ai/funds/health-innovations) — Seed, Series A
- Oost NL (https://capitalatlas.ai/funds/oost-nl) — Series A